2007: Sjogren's Syndrome

Sjogren's Syndrome

1077

Development of Autoimmune Exocrinopathy Resembling Sjogren's Syndrome in Rbap48 Transgenic Mice

1078

Lymphotoxin-Beta Receptor Axis Modulates HEV Status and Gene Expression Patterns in Exocrine Glands in the NOD Mouse Model of Sjogren's Syndrome

1079

Expression of Proteasomal Immunosubunit Beta1i (LMP2) is Suppressed in Inflammatory Infiltrates of Minor Salivary Glands in Sjögren´s Syndrome

1080

Constricture of the Excretory Duct in Parotid Salivary Glands of a Mouse Model of Sjögren’s Syndrome that Exhibits Decreased Salivary Flow

1081

Persistance of Maternally Transfered Anti-Ro 274 Peptide Antibodies in a Sjogrens Syndrome Mouse Model

1082

Human Chorionic Gonadotropin Prevents Sjögren's-Like Exocrinopathy in Mice

1083

New Murine Model for Sjogren's Syndrome Established by M3 Muscarinic Acethylcholine Receptor Immunization

1084

Novel Genetic Associations with Primary Sjögren’s Syndrome

1085

Association of an Irf-5 Gene Functional Polymorphism with SjöGren’S Syndrome

1086

Fcg Receptor IIa and IIIa Polymorphisms in Primary Sjögren Syndrome

1087

Is Id3 Gene Involved in Human Primary Sjögren’s Syndrome ?

1088

Up-Regulation of Interferon Inducible 150kDa ADAR1 Gene Expression and Altered Editing of the Interferon Alpha Receptor 2 (IFNAR2) Gene Transcripts in Peripheral Blood Mononuclear Cells (PBMCs) of Primary Sjögren's Syndrome (pSS) Patients

1089

Quantitative Levels of Anti-ssa, Anti-ssb, and Anti-rnp Antibodies in Primary SjöGren’S Syndrome: Correlation with Baff, B Cell Activation Markers, and Disease Activity

1090

Clinical and Immunological Expression of the Epidemiologic Subsets of Primary Sjögren’s Syndrome. Multicenter Study of 1000 Patients

1091

Longitudinal Analysis of Lymphocyte Subsets in Patients with Primary Sjogren's Syndrome (pSS) Treated with Rituximab: Results from an Open-Label Clinical Trial

1092

Objective Measures in Sjögren’s Syndrome are Strongly Associated with Each Other but not with Sicca Symptoms: Analysis of 564 Enrollees in the SICCA International Registry and Repository

1093

Increased Psychiatric Comorbidity in Primary SS.-Association with Autoantibodies Against Neuropeptides

1094

Safety and Efficacy of Rituximab in Sjogren's Syndrome: Results of a Randomised, Placebo Controlled Pilot Study

1095

Pulmonary Arterial Hypertension (PAH) in Primary Sjögren’s Syndrome: Report of 9 Cases

1096

Effect of Nizatidine, a H2 Receptor Antagonist on the Xerostomia in Patients with Sjögren's Syndrome

1097

The Effect of Modafinil on Fatigue and Cognitive Function in Patients with Sjögren’s Syndrome

1098

Fatigue, Discomfort, and Burden of Illness Among Sjögren’s Syndrome (SS) Patients in the United States

1099

Prevalence of Sensory Symptoms in Primary Sjögren’s Syndrome (pSS) and Relationship of Neuropathic Symptoms to Depression and Fibromyalgia

1100

Prevalence, Severity and Predictors of Fatigue in Primary Sjogren's Syndrome

1101

Anti-Cyclic Citrullinated Peptide Antibodies in Primary Sjogren's Syndrome may be Associated to Non-Erosive Synovitis

1102

Rituximab Therapy for Primary Sjögren's Syndrome (pSS): An Open-Label Trial

1103

Etiology of Sleep Disturbance in Sjogren's Syndrome

See more of: ACR Abstract Submission Poster Sessions

<< Previous Session Level | Next Session Level >>